UCB (OTCMKTS:UCBJY) Raised to Moderate Sell at Jefferies Financial Group

UCB (OTCMKTS:UCBJY) was upgraded by investment analysts at Jefferies Financial Group to a “moderate sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research firms have also recently commented on UCBJY. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Finally, Zacks Research lowered UCB from a “hold” rating to a “strong sell” rating in a report on Thursday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

UCB Stock Performance

UCB stock opened at $143.03 on Monday. UCB has a 12 month low of $94.75 and a 12 month high of $168.76. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The business has a 50 day simple moving average of $144.16 and a 200-day simple moving average of $147.52.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.